CD34 and acute myeloid leukemia: Studies have shown, however, that the presence of NPM1 imprint AML clinical and biological features, as a reduced expression or absence of CD34, and seems to be an initiating genetic event in approximately 1/3 of cases of AML, and thus extremely useful in determining minimal residual disease [21-24].